Mota LMH, Cruz BA, Brenol CV, et al. Consensus of the Brazilian Society of Rheumatology for diagnosis and early assessment of rheumatoid arthritis. Revista Brasileira de Reumatologia 2011; 51(3): 199–219.
Markatseli TE, Papagoras C, Drosos AA. Prognostic factors for erosive rheumatoid arthritis. Clinical & Experimental Rheumatology 2010; 28(1): 114–123.
Kroot EJJA, De Jong BAW, Van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2000; 43(8): 1831–1835.
Vencovský J, Macháček S, Šedová L, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Annals of the Rheumatic Diseases 2003; 62(5): 427–430.
Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five-year radiographic damage. Annals of the Rheumatic Diseases 2003; 62(2): 120–126.
Maddali Bongi S, Manetti R, Melchiorre D, et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 2004; 37(6–7): 495–501.
Forslind K, Ahlmén M, Eberhardt K, et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CCP). Annals of the Rheumatic Diseases 2004; 63(9): 1090–1095.
Quinn MA, Gough AKS, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology 2006; 45(4): 478–480.
Nell VPK, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Annals of the Rheumatic Diseases 2005; 64(12): 1731–1736.
Rönnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5-year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Annals of the Rheumatic Diseases 2005; 64(12): 1744–1749.
Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases 2005; 64(2): 196–201.
Sanmartí R, Gómez-Centeno A, Ercilla G, et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: A two-year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clinical Rheumatology 2007; 26(7): 1111–1118.
Kaltenhäuser S, Pierer M, Arnold S, et al. Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rheumatology 2007; 46(1): 100–104.
Hetland M L, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis–MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomized CIMESTRA trial. Annals of the Rheumatic Diseases 2010; 69(10): 1789–1795.
Kim HH, Kim JH, Park SH, et al. Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients. The Korean Journal of Internal Medicine 2010; 25(2): 201–206.
De Rycke L, Peene I, Hoffman IEA, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: Diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Annals of the Rheumatic Diseases 2004; 63(12): 1587–1593.
Mewar D, Coote A, Moore DJ, et al. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Research & Therapy 2006; 8(4): R128.
Silva AF, Matos AN, Lima ÁMS, et al. Association of anti-cyclic citrullinated peptide antibody and severe rheumatoid arthritis. Revista Brasileira de Reumatologia 2006; 46: 165–173.
Del Amo NDV, Bosch RI, Manteca CF, et al. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clinical and Experimental Rheumatology 2006; 24(3): 281–286.
Alexiou I, Germenis A, Ziogas A, et al. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskeletal Disorders 2007; 8(1): 1–7.
Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: Results from a 10-year longitudinal study. Annals of the Rheumatic Diseases 2008; 67(2): 212–217.
Nieto-Colonia AM, Santos WS, Keusseyan SP, et al. Antibodies to citrullinated peptides are not associated with the rate of joint destruction in patients with a well-established diagnosis of rheumatoid arthritis. Brazilian Journal of Medical and Biological Research 2008; 41: 188–192.
Gupta R, Thabah M, Aneja R, et al. Usefulness of anti-CCP antibodies in rheumatic diseases in Indian patients. Indian Journal of Medical Sciences 2009; 63(3): 92–100.
Kastbom A, Strandberg G, Lindroos A, et al. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Annals of the Rheumatic Diseases 2004; 63(9): 1085–1089.
Korkmaz C, Us T, Kaşifoğlu T, et al. Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clinical Biochemistry 2006; 39(10): 961–965.
Mota LM, Neto LS, Burlingame RW, et al. Disability and quality-of-life are not influenced by the prevalence of autoantibodies in early rheumatoid arthritis patients—Results of the Brasília Cohort. Revista Brasileira de Reumatologia 2012; 52(6): 819–829.
Hui L, Wuqi S, Yang L, et al. Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity. Clinical Rheumatology 2010; 29(4): 413–417.
Shidara K, Inoue E, Hoshi D, et al. Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatology International 2012; 32(2): 361–366.
Choe JY, Bae J, Lee H, et al. Relation of rheumatoid factor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: Cross-sectional study. Rheumatology International 2013; 33(9): 2373–2379.
da Mota LMH, dos Santos Neto LL, de Carvalho JF, et al. The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years. Rheumatology International 2012; 32(12): 3807–3812.
Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 1988; 31(3): 315–324.
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & Rheumatism 2010; 62(9): 2568–2581.
Aletaha D, Nell V P K, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Research & Therapy 2005; 7(4): 1–11.
Ferraz MB, Oliveira LM, Araujo PM, et al. Crosscultural reliability of the physical ability dimension of the health assessment questionnaire. The Journal of Rheumatology 1990; 17(6): 813–817.
Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. The Journal of Rheumatology 1999; 26(3): 743–745.
Østergaard M, Peterfy C, Conaghan P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. The Journal of Rheumatology 2003; 30(6): 1385–1386.
Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2006; 54(1): 38–46.
Pedersen M, Jacobsen S, Garred P, et al. Strong combined gene–environment effects in anti–cyclic citrullinated peptide–positive rheumatoid arthritis: A nationwide case–control study in Denmark. Arthritis & Rheumatism 2007; 56(5): 1446–1453.
Pedersen M, Jacobsen S, Klarlund M, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Research & Therapy 2006; 8(4): R133.
Goeldner I, Skare TL, de Messias Reason IT, et al. Association of anticyclic citrullinated peptide antibodies with extra-articular manifestations, gender, and tabagism in rheumatoid arthritis patients from southern Brazil. Clinical Rheumatology 2011; 30(7): 975–980.
Aletaha D, Smolen J. The implified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology 2005; 23(5): S100–S108.
Smolen J S, Landewé R, Breedveld F C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases 2014; 73(3): 492–509.
Ravindran V, Rachapalli S. An overview of commonly used radiographic scoring methods in rheumatoid arthritis clinical trials. Clinical Rheumatology 2011; 30(1): 1–6.
Hafström I, Engvall I L, Rönnelid J, et al. Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: A randomized study. BMJ Open 2014; 4(7): e005246. doi: 10.1136/bmjopen-2014-005246.
Gandjbakhch F, Haavardsholm E A, Conaghan P G, et al. Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: Results from a follow-up MRI study of 254 patients in clinical remission or low disease activity. The Journal of Rheumatology 2014; 41(2): 398–406.
Conaghan PG, Emery P, Østergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: Results of the GO-FORWARD trial. Annals of the Rheumatic Diseases 2011; 70(11): 1968–1974.
Østergaard M, Emery P, Conaghan P G, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis & Rheumatism 2011 63(12): 3712–3722.
Gandjbakhch F, Conaghan P G, Ejbjerg B, et al. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. The Journal of Rheumatology 2011; 38(9): 2039–2044.
Brown A K, Quinn M A, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2006; 54(12): 3761–3773.
Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2008; 58(10): 2958–2967.
